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Abstract
Background
Despite that over 90 million pregnancies are at risk of Plasmodium vivax infection annually,
little is known about the epidemiology and impact of the infection in pregnancy.
Methodology and principal findings
We undertook a health facility-based prospective observational study in pregnant women
from Guatemala (GT), Colombia (CO), Brazil (BR), India (IN) and Papua New Guinea
PNG). Malaria and anemia were determined during pregnancy and fetal outcomes
assessed at delivery. A total of 9388 women were enrolled at antennal care (ANC), of whom
53% (4957) were followed until delivery. Prevalence of P. vivax monoinfection in maternal
blood at delivery was 0.4% (20/4461) by microscopy [GT 0.1%, CO 0.5%, BR 0.1%, IN
0.2%, PNG 1.2%] and 7% (104/1488) by PCR. P. falciparum monoinfection was found in
0.5% (22/4463) of women by microscopy [GT 0%, CO 0.5%, BR 0%, IN 0%, PNG 2%].
P. vivax infection was observed in 0.4% (14/3725) of placentas examined by microscopy
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005606 June 12, 2017 1 / 22
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Bardajı´ A, Martı´nez-Espinosa FE, Are´valo-
Herrera M, Padilla N, Kochar S, Ome-Kaius M, et al.
(2017) Burden and impact of Plasmodium vivax in
pregnancy: A multi-centre prospective
observational study. PLoS Negl Trop Dis 11(6):
e0005606. https://doi.org/10.1371/journal.
pntd.0005606
Editor: Photini Sinnis, Johns Hopkins Bloomberg
School of Public Health, UNITED STATES
Received: November 24, 2016
Accepted: April 27, 2017
Published: June 12, 2017
Copyright: This is an open access article, free of all
copyright, and may be freely reproduced,
distributed, transmitted, modified, built upon, or
otherwise used by anyone for any lawful purpose.
The work is made available under the Creative
Commons CC0 public domain dedication.
Data Availability Statement: This information will
only be available after acceptance.
Funding: The PregVax collaborative project was
funded by the European Union Seventh Framework
Programme (FP7/2007-2013) under grant
agreement number PREGVAX FP7-HEALTH-
201588. It also received co-funding from the
Malaria in Pregnancy Consortium (MiPc) through a
grant from the Bill & Melinda Gates Foundation
[Grant No. 46099], and from the Ministry of
and in 3.7% (19/508) by PCR. P. vivax in newborn blood was detected in 0.02% (1/4302) of
samples examined by microscopy [in cord blood; 0.05% (2/4040) by microscopy, and 2.6%
(13/497) by PCR]. Clinical P. vivax infection was associated with increased risk of maternal
anemia (Odds Ratio-OR, 5.48, [95% CI 1.83–16.41]; p = 0.009), while submicroscopic vivax
infection was not associated with increased risk of moderate-severe anemia (Hb<8g/dL)
(OR, 1.16, [95% CI 0.52–2.59]; p = 0.717), or low birth weight (<2500g) (OR, 0.52, [95% CI,
0.23–1.16]; p = 0.110).
Conclusions
In this multicenter study, the prevalence of P. vivax infection in pregnancy by microscopy
was overall low across all endemic study sites; however, molecular methods revealed a sig-
nificant number of submicroscopic infections. Clinical vivax infection in pregnancy was asso-
ciated with maternal anemia, which may be deleterious for infant’s health. These results
may help to guide maternal health programs in settings where vivax malaria is endemic;
they also highlight the need of addressing a vulnerable population such as pregnant women
while embracing malaria elimination in endemic countries.
Author summary
More than 90 million pregnancies are exposed to P. vivax infection every year. While it is
well known that pregnant women have an increased risk of P. falciparum infection and
disease, much less is known on the epidemiology and the impact of P. vivax in pregnancy.
A health-facility based observational study was conducted in pregnant women living in
five vivax endemic countries aimed to determine the burden of the infection in pregnancy
and its impact on the mother and the newborn health. We found that the prevalence of
P. vivax malaria in pregnant women attending the routine antenatal clinic visits was over-
all low across all sites, however submicroscopic infections were unexpectedly high in
some areas. Pregnant women with clinical malaria experienced an increased risk of ane-
mia, which may have a deleterious impact on infant health. These findings may be useful
for guiding maternal health programs in vivax endemic settings, as well as for malaria
elimination activities.
Introduction
More than a third of the world0s population is at risk of Plasmodium vivax infection, 90% of
whom live in the Asia and the Pacific regions, while the rest live in the American (6%) and
African (3%) regions. [1–3] In comparison with P. falciparum, P. vivax infection has received
little attention mostly because it has been considered a relatively benign disease. [3, 4] How-
ever, in recent years due to the increasing evidence of the severity of P. vivax infection and the
recognition of its economic impact in endemic countries, a greater interest has been devoted
to this neglected and complex species. [3, 5] This renewed interest is also enhanced by the rec-
ognition that with intensified control efforts P. vivax has become the predominant malaria spe-
cies and the major challenge to malaria elimination outside Africa.
It is well recognized that pregnant women have an increased risk of P. falciparum infection
and disease, and its effects on maternal and infant health have been well documented in sub-
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Saharan Africa. [6] Less is known about the burden of P. vivax in pregnancy and its impact on
maternal and infant health. In 2007, it was estimated that the number of pregnancies at risk of
P. vivax was at least 92 million globally. [7] Some studies on the effect of P. vivax infection in
pregnancy have suggested that the infection is associated with maternal anemia, miscarriage,
congenital malaria and preterm delivery, as well as with severe disease. [8–17] These studies
were mostly done in Asia, and with some exceptions,[12, 18–20] were based on limited num-
bers or case reports, thus providing an incomplete picture of the overall burden and impact of
P. vivax in pregnancy. In particular, there were limited data from Latin America.
A comprehensive description of the burden and impact of P. vivax infection in pregnancy
across different malaria transmission settings is needed to guide control strategies. We pres-
ent here the results of a prospective observational study in pregnant women exposed to vivax
malaria that aimed to determine the burden of P. vivax malaria and its impact on pregnancy
outcomes. The study followed a multicenter approach including different epidemiological
settings broadly representing of P. vivax endemic areas; one Asian country, one country
from the Pacific region and three countries from the Americas. The objectives of the study
were to estimate the prevalence of P. vivax infection at different time points overall and for
each of the sites, and the incidence of P. vivax malaria during pregnancy. It also aimed to
assess the clinical impact of P. vivax infection during pregnancy on maternal health and fetal
outcomes.
Methods
Ethics
The study protocol was reviewed and approved by the national and/or local ethics review
boards in each of the study sites, the Institutional Review Board (IRB) of the Centers for Dis-
ease Control and Prevention (CDC), and the Hospital Clinic of Barcelona Ethics Review Com-
mittee. The study was conducted in accordance with the Good Clinical Practice Guidelines,
the Declaration of Helsinki, and local rules and regulations of each partner country.
Study design and study areas
This was a health facility-based prospective observational study of pregnant women attending
routine antenatal care (ANC) clinics undertaken between June 2008 and October 2011 in five
P. vivax endemic countries—Colombia (CO), Guatemala (GT), Brazil (BR), India (IN) and
Papua New Guinea (PNG)–of different malaria endemicity characteristics (Table 1). The his-
toric levels of malaria transmission varied across study sites from hypoendemic in Guatemala,
India and Colombia, mesoendemic in Brazil, to hyperendemic in PNG. P. vivax was the pre-
dominant species in all sites except for PNG where P. vivax co-existed with P. falciparum
(50%) and other species (P. malariae and P. ovale, 5%).
Study procedures
Unselected pregnant women of any age, gestational age, and parity, attending the ANC clinic
at each study site, independently of parasitological or disease status, were invited to participate,
and after signing a written informed consent were recruited into the study. There were four
study visits: recruitment visit, coinciding with an ANC visit; two subsequent scheduled ANC
visits one month apart; and at delivery. Project personnel were trained on study procedures
that were standardized across all study sites. At each study visit and regardless of the presence
of symptoms suggestive of malaria, a capillary blood sample was collected to prepare two thick
and thin blood smears and two filter papers (Whatmann 3MM) to determine Plasmodium
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parasitemia. From the same samples the hemoglobin (Hb) concentration was measured at
enrolment, at scheduled ANC study visits, at delivery and at any other time the woman was
suspected to have malaria. In addition, demographic, obstetric and clinical information were
recorded on standardized questionnaires. Pregnant women were encouraged to deliver at the
Table 1. Characteristics of the study sites.
Country Colombia Guatemala Brazil India Papua New Guinea
Sites Tierralta, Co´rdoba Fray Bartolome´ de las
Casas, Alta Verapaz
Manaus, Amazonas Bikaner, Rajasthan Madang
Location Rural Rural Peri-urban Peri-urban Peri-urban & Rural
Malaria transmission Hypoendemic Hypoendemic Mesoendemic Hypoendemic Hyperendemic
Endemicity Perennial transmission Perennial transmission,
peak Apr-Nov
Perennial transmission,
peak Jul-Aug
Seasonal transmission,
Sep-Dec, Mar-Jun
Perennial transmission
Plasmodium species 70% P.vivax, 30% P.
falciparum
100% P.vivax a 86% P.vivax, 14% P.
falciparumb
97% P.vivax, 3% P.
falciparum
45% P.vivax, 50% P.
falciparum, 5% P.ovale/
malariae
Vector Anopheles nuneztovari,
An.darlingi
Anopheles albimanus,
An.darlingi, An.
vestitipennis
An. darlingi An.subpictus, An.
stephensi, An.
culicifacies, An.
annularis
An.punctulatus, An.
koliensis, An.faranti
Coverage ANC attendance (at
least 4 ANC visits)
80% 80% 80% 40% 55%c
ITNs Coverage (ownership) 40% 90% 7% No ITNs 75%
Guidelines for treatment of P.
vivax uncomplicated malaria
in pregnancy
CQ full coursed + CQ
weekly until delivery + PQ
14d 6m post-partum
CQ full course + CQ
weekly until delivery + PQ
14d post-partum
CQ full course + CQ
weekly 12w + PQ 14d
6m post-partum
CQ full course CQ full course + SP full
dosee
Guidelines for treatment of P.
falciparum uncomplicated
malaria in pregnancy
1st trimester: QNN + CLIN
7df 2nd-3rd trimesters: ALg
CQ full course + PQ 3d
post-partum
1st trimester: QNN 3d +
CLIN 5d 2nd-3rd
trimesters: AL
1st trimester: QNN 2nd-
3rd trimesters: ACTs
CQ full course + SP full
doseh
Guidelines for prevention of
malaria in pregnancy
ADI at each ANC visits PCD + ITNsi ADI at each ANC visits PCD (CQ full course + SP) at 1st
ANC visit + CQ weekly until
delivery + PCD
Abbreviations: CQ: Chloroquine, PQ: Primaquine, SP: Sulfadoxine-pyrimethamine, QNN: Quinine, CLIN: Clindomycin, AL: Artemeter-Lumefantrine, ITNs:
Insecticide-treated bednets, ADI: Active Detection of Infection, ACTs: Artemisin-combined therapy, PCD: Passive detection of cases.
a No P. falciparum cases reported in the area since 2009.
b Data from 2009.
c 79% of women completed at least 1 ANC visit.
d 150mg CQ base (tab 250 mg), 4 tab 1st day and 3 tab 2nd and 3rd day.
e 500mg sulfadoxine/25mg pyrimethamine (3tab, monodosis).
f QNN: 10mg/kg every 8h, CLIN: 10mg/kg every 12h.
g AL: Artemeter (20mg)-Lumefantrine (120mg), twice per day over 3 days.
h New protocol adopted in 2009. Uncomplicated P.falciparum malaria: AL. Uncomplicated P.vivax malaria: AL+PQ.
i Indoor residual spraying and larvicides in general population.
Source of data: Colombia: Montoya-Lerma J, Solarte YA, Giraldo-Caldero´n GI, Quiñones ML, Ruiz-Lo´pez F, Wilkerson RC, Gonza´lez. Malaria vector
species in Colombia: a review. Mem Inst Oswaldo Cruz 2011, 106:223–238. Chaparro P, Padilla J, Vallejo AF, Herrera S: Characterization of a malaria
outbreak in Colombia in 2010. Malar J 2013, 12:330. Guı´a de atencio´n me´dica para el diagno´stico y tratamiento de la malaria. Ministerio de Salud de
Colombia. 2010. Guatemala: Padilla N, P. Molina, J. Juarez, D. Brown and C.Cordon-Rosales. Potential malaria vectors in northern Guatemala (Vectores
potenciales de malaria in la region norte de Guatemala). J Am MosqControl Assoc 1992;8:307–8. Brazil: http://portalweb04.saude.gov.br/sivep_malaria/
default.asp. Accessed 15 January 2017. India: Kochar DK, Sirohi P, Kochar SK, Budania MP, Lakhotia JP. Dynamics of malaria in Bikaner, Rajasthan, India
(1975–2006). J Vector Borne Dis. 2007 Dec;44(4):281–4. PNG: Papua New Guinea National Department of Health: National Malaria Treatment Protocol.
Port Moresby: National Department of Health ed., 1st edition; 2009. Marfurt J, Mu¨eller I, Sie A, Maku P, Goroti M, Reeder JC, Beck HP, Genton B. Low
efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea. Am J
Trop Med Hyg. 2007 Nov;77(5):947–54. Barnadas C, Koepfli C, Karunajeewa HA, Siba PM, Davis TM, Mueller I. Characterization of treatment failure in
efficacy trials of drugs against Plasmodium vivax by genotyping neutral and drug resistance-associated markers. Antimicrob Agents Chemother. 2011
Sep;55(9):4479–81.
https://doi.org/10.1371/journal.pntd.0005606.t001
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study health facility. In case of home delivery, they were advised to come to the study health
facility within the first week of giving birth.
A passive surveillance system to identify study women presenting with clinical malaria was
set up at each study health facility. If the women reported any signs and/or symptoms sugges-
tive of clinical malaria, a capillary blood sample was collected to prepare two thick and thin
blood smears and two filter papers to determine Plasmodium parasitemia, and for determina-
tion of Hb concentration.
At delivery, the pregnancy outcome and the clinical information on the mother and the
neonate were collected. Placental blood from all women delivering at the health facility was
collected onto filter paper for PCR molecular analysis, and two impression smears were stained
with Giemsa and read following standard procedures for parasitemia determination. [21] For
the preparation of the impression smears a 2.5x2.5 cm3 sample from the placenta, that should
include the full thickness of the tissue from the maternal to the fetal side, was cut and put in
contact with the slide after being dried with a piece of filter paper. In a randomly selected
subsample of women (10%) a placental biopsy was collected, following a similar procedure
(2.5x2.5 cm3 sample) to that for the preparation of the impression smear. The biopsy was kept
at 4˚C in 50 mL of 10% neutral buffer formalin, processed for histological examination, and
stained with haematoxylin and eosin as previously described. [22] The histological examina-
tion of placental biopsies for malaria infection was performed by local pathologists trained for
the purposes of the study (S1 File). Cord blood samples were collected after birth for parasite-
mia determination. As soon as the umbilical cord was clamped, cut, and separated from the
newborn study trained staff collected 5mL cord blood sample taken from the cord with a
syringe and needle. Cord blood was used for preparation of two thick and thin blood smears
to determine Plasmodium parasitemia, and two filter papers to perform PCR molecular analy-
sis. Newborn samples were collected by heel prick after medical assessment was complete and
within the first 12 hours of life also for parasitemia determination.
In GT, BR and PNG gestational age was assessed by the Ballard’s method for deliveries that
occurred at the health facility within the first 72 hours after birth [23]. In CO and IN gesta-
tional age was assessed by ultrasound assessment performed at enrolment. All newborns were
weighed on a digital scale, accurate to the nearest gram, within the first 2 hours of life and
examined for any clinical abnormalities. For deliveries occurred at home, the study personnel
obtained information on the pregnancy outcome through home visits. All women and new-
borns with malaria infection or anemia were treated according to the national guidelines in
each country. Strategies for malaria control in pregnancy differed across study sites. While
these relied on active detection of infection with microscopy at each ANC visit in some coun-
tries, in other countries passive detection of cases, or weekly prophylaxis with chloroquine
(CQ) until delivery were carried out (Table 1).
At enrolment a subsample of 1500 women (300 per study site) were randomly selected for
the determination of the prevalence of P. vivax and P. falciparum infection by PCR methods.
Likewise, a subsample of 1500 women (300 per study site) was randomly selected at delivery
for the same purpose. The 1500 women from whom samples were obtained at delivery were
different from those selected at enrolment. A total of 500 placental samples (100 per site) and
500 cord blood samples (100 per site) were also analysed following same methodology. A sim-
ple random sampling method was used for the selection of women in each country, and for
each time point and compartment. The sample size for prevalence by PCR was agreed among
study investigators according to preliminary results of the first 100 selected samples in each
site that showed a prevalence of P. vivax monoinfection of 7.5% by PCR, and on the availability
of resources for molecular analyses in the study. PCR assays were not performed on newborn
blood samples.
Plasmodium vivax infection in pregnancy
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To estimate the impact of submicroscopic P. vivax and P. falciparum infections on maternal
anemia and low birth weight (LBW), a nested case-control study was conducted. All countries
contributed to this pooled analysis. A definition for moderate-severe anemia as Hb less than
8g/dL was agreed for the purpose of the analysis. All moderate-severe anemia cases (n = 342),
and LBW cases (<2500g) (n = 327) existing across countries for which a blood smear and a
filter paper were available, were included in the case control analysis. A total of 414 controls
to anemia cases, and a total of 410 controls to LBW cases, were randomly selected. Logistic
regression models used to evaluate the impact of P.vivax submicroscopic infections on anemia
and LBW were adjusted by site and P. falciparum infections. Similarly, for the evaluation of the
impact of P. falciparum submicrocopic infections, models were adjusted by site and P. vivax
infections.
Laboratory methods
Giemsa-stained thick and thin blood slides were read onsite in all countries following WHO
standard quality-controlled procedures to establish parasite presence and density of Plasmo-
dium asexual stages. [24] Two independent expert malaria microscopists read all slides and
results were registered in two separate forms. Discrepant results (positive vs. negative) were
resolved by a third reading done by a different microscopist. A blood slide was declared as neg-
ative only when no parasites were found after reading 200 fields. Results were expressed in par-
asites/μL after counting the number of parasites per 500 white blood cells or reaching 500
parasites; counting was normalized using estimated leukocyte counts of 8000/μL. External vali-
dation of a blood slides subsample (100 slides per country) was done at the Hospital Clinic and
at the Hospital Sant Joan de Deu, in Barcelona, Spain. Hb was measured by Coulter Counter
(except in PNG where it was done by Hemocue, HemoCue, Ltd, Angelhom, Sweden; accuracy
of 0.1 g/dL) using 50–100 μL collected in a 0.5mL EDTA tube (microtainer).
Molecular detection of Plasmodium species in samples from CO, GT, BR and PNG was per-
formed by Real Time PCR at the Istituto Superiore di Sanità (ISS) in Rome, Italy. Samples
from India were analysed, due to local regulatory requirements, at the International Center for
Genetic Engineering and Biotechnology (ICGEB), in New Delhi using the same protocol as
that at ISS but adapted for the sake of instrument sensitivity (3rd step at amplification was
72˚C for 25 sec instead of 72˚C for 5 sec). DNA was extracted from whole blood-spot filter
paper from maternal peripheral blood collected at ANC, at delivery and during passive case
detection, and from placental and cord blood using Purelink Genomic DNA Kit (Invitrogen).
P. vivax and P. falciparum infections were detected with a LightCycler 480 system (Roche).
Species-specific primers and Taqman probes were selected from the sequence of the small 18S
rRNA subunit as previously described by Veron et al 2009. [25] Briefly, pre-incubation was at
95˚C for 10 min; amplification at 95˚C for 10 sec, 50˚C for 20 sec and 72˚C for 5 sec for 50
cycles. All reactions were in duplicate in a final volume of 20 μL. The sensitivity of the PCR
assay performed at the ISS for detection of P. falciparum infections was between 10–100 times
higher in comparison to the microscopy. An external validation of the PCR methods used by
the ISS and the ICGEB, for detection of P. vivax and P. falciparum species, was performed by
the Malaria in Pregnancy Consortium (MiPc) (http://www.mip-consortium.org) in a subset of
20 samples. Internal validation between ISS and ICGEB was also done.
Data management and statistical analysis
A standardised system for data entry, data management, and statistical analysis was estab-
lished. All clinical and laboratory data were collected using standardised questionnaires. The
data collection and management was performed using the OpenClinica open source software,
Plasmodium vivax infection in pregnancy
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version 2.0. Copyright OpenClinica LLC and collaborators, Waltham, MA, USA, www.
OpenClinica.com. All data were double entered by two independent data clerks at each of the
sites. There was a specific URL link to access the data entry software. In PNG data were dou-
bled-entered into form-specific databases (FoxPro 90, Microsoft, USA). Validation and clean-
ing were done using the same software, and statistical analysis was performed using Stata 13
(Stata Corporation, College Station, TX, USA). Differences between proportions were com-
pared using the Pearson0s chi-squared test or Fisher’s exact test depending on type of variables.
For continuous variables, Student’s T-tests were used to compare the groups. Incidence rates
were calculated as the number of new episodes/person-year at risk using the Poisson distribu-
tion in the exposed and unexposed groups, with primigravid women as the comparator group.
The impact of P. vivax infection on maternal and newborn health was determined through a
multicenter-pooled analysis. The case control study for submicroscopic infections with and
anemia was analyzed using logistic regression models. We adjusted all regression models for
possible operational confounding variables such as country and previous malaria episodes. In
the analyses of P. falciparum infections, they were included in the models as being free of
P. vivax (see definitions section). Likewise, in the analyses of P. vivax infections, they were
included as being free of P. falciparum. Multivariate analyses were performed by a forward-
stepwise procedure, using p<0.05 and p>0.10 from the likelihood ratio test, as enter and
remove criteria respectively. Results from the estimated models were expressed as OR and 95%
CI. Missing values were coded as such and excluded from analysis.
Definitions
P. vivax microscopic monoinfection was defined as the presence of asexual P. vivax parasites of
any density and absence of other Plasmodium species on the blood smear. P. vivax clinical
malaria episode was defined as the latter plus any signs or symptoms suggestive of malaria (axil-
lary temperature37.5˚C or history of fever in the last 24 hours, headache, arthromyalgias,
and/or pallor). P. vivax submicroscopic infection was defined as a PCR that was positive for
P. vivax and negative for P. falciparum, with a concomitant blood film negative by microscopy.
P. falciparum microscopic monoinfection was defined as the presence of asexual P. falciparum
of any density and absence of other Plasmodium species on the blood smear. P. falciparum clin-
ical malaria episode was defined as the latter plus any signs or symptoms suggestive of malaria.
P. falciparum submicroscopic infection was defined as a PCR that was positive for P. falciparum
and negative for P. vivax, with a concomitant blood film negative by microscopy. The duration
of any single malaria episode was estimated as 28 days.
Congenital malaria was defined as presence of asexual Plasmodium parasites of any species
in the cord blood or in the newborn0s peripheral blood at delivery, regardless of clinical symp-
toms or signs in the neonate. Placental infection was classified according to a previously estab-
lished definition. [21] Briefly, acute infection was defined as the presence of parasites, with
absent or minimal pigment deposition within fibrin or cells within fibrin, chronic infection as
the presence of parasites and a significant amount of pigment deposition, and past infection as
the presence of pigment with absence of parasites. Prematurity was defined as gestational
age< 37 weeks. LBW was defined as birth weight <2500g.
Results
Baseline characteristics of study women
A total of 9388 pregnant women were recruited across all sites (2043 in CO; 2009 in GT; 1657
in BR; 1982 in IN; 1697 in PNG), and 4957 (53%) of them were followed up until delivery (Fig
1). Table 2 the baseline characteristics of the study participants by site (S1 Table). Mean age of
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study women was 23.6 years [standard deviation (SD) = 5.6], mean gestational age 23 weeks
(SD = 8); nearly 40% (3759/9468) of the women were primigravidae. At enrolment, overall
mean Hb level was 10.5 g/dL (SD 1.8), and 57% (5201/9105) of women were anemic
(Hb<11g/dL). Around 70% of women (6471) were enrolled at their first ANC visit versus at
later ANC visit.
Prevalence of P. vivax mono-infection
The overall prevalence of P. vivax mono-infection detected by microscopy was 0.8% (73/
9299) at enrolment and 0.4% (20/4461) at delivery. Of those women who were parasitemic
for P. vivax 57.6% (42/73) were symptomatic at enrolment and 20% (4/20) at delivery. The
prevalence of P. vivax mono-infection by PCR assessed in a subsample of women was 8.5%
(124/1455) at enrolment and 6.9% (104/1488) at delivery, and of those 9.7% (12/124) and
4.8% (5/104) reported symptoms, respectively (Fig 2).
Prevalence of P. falciparum mono-infection
The overall prevalence of P. falciparum mono-infection detected by microscopy was 1.3%
(124/9305) at enrolment and 0.5% (22/4463) at delivery. Of those women who were
Fig 1. Study profile. * Number recruited at antenatal care per country: 2009 in Guatemala, 2043 in
Colombia, 1657 in Brazil, 1982 in India, and 1697 in PNG.
https://doi.org/10.1371/journal.pntd.0005606.g001
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parasitemic for P. falciparum 16.1% (20/124) were symptomatic at enrolment and 27.3% (6/
22) at delivery. No P. falciparum infection was detected by microscopy in GT and BR neither
at enrolment or delivery, nor in India at delivery. The prevalence of P. falciparum mono-infec-
tion by PCR assessed in a subsample of women was 6.9% (80/1157) at enrolment and 2% (24/
1191) at delivery, and of those 10% (8/80) and 12.5% (3/24) reported symptoms, respectively
(Fig 3).
Mixed infections
There were no mixed infections (P. vivax plus P. falciparum) detected by microscopy during
pregnancy or at delivery in CO, GT, BR and IN. In PNG mixed infections were observed in
9/818 (1.1%) of placental impression smears only. The prevalence of mixed infections detected
Table 2. Baseline characteristics of study women at enrolment.
Overall Colombia Guatemala Brazil India Papua New Guinea
Participants (N) 9388 2043 2009 1657 1982 1697
Age (years) * 23.6 (5.6) [9345] 22.2 (5.7) [2043] 24.4 (6.6) [2001] 23.5 (6.2) [1655] 23.1 (3.4) [1980] 25.0 (5.4) [1677]
Gestational age (weeks) * 24 (8) [8539] 21 (9) [2042] 26 (8) [1978] 22 (8) [1624] 24 (6) [1979] 23 (5) [915]
n (%) n (%) n (%) n (%) n (%) n (%)
Gestational age † 1st trimester 891 (11) 453 (22) 131 (7) 231 (14) 35 (2) 41 (4.4)
2nd trimester 3608 (42) 805 (39) 623 (31) 731 (45) 984 (50) 465 (51)
3rd trimester 4040 (47) 785 (38) 1224 (62) 662 (41) 960 (49) 409 (45)
Weight (kg) * 57.7 (10.2) [9224] 58.1 (10.6) [2015] 58.6 (9) [1999] 61.8 (11.8) [1608] 54.6 (9.5) [1942] 55.7 (8) [1660]
Height (cm) * 154.1 (6.1) [9328] 156.3 (5.8) [2025] 150.9 (5.7) [2005] 154.1 (5.9) [1654] 155 (5.9) [1980] 154.3 (6) [1664]
Haemoglobin (gr/dL) 10.5 (1.8) [9105] 11.2 (1.7) [2033] 11.2 (1.3) [1761] 11.5 (1.1) [1642] 9.1 (1.6) [2025] 9.5 (1.5) [1644]
n (%) n (%) n (%) n (%) n (%) n (%)
Gravidity Primigravidae 3719 (40) 672 (33) 726 (36) 532 (32) 1001 (51) 788 (47)
1 to 3
pregnancies
3680 (39) 863 (42) 681 (34) 663 (40) 893 (45) 580 (34)
4
or > pregnancies
1972 (21) 508 (25) 596 (30) 462 (28) 87 (4) 319 (19)
Overall anaemia at baseline (Hb<11 g/dl) 5201 (57.1) 867 (43) 661 (37.5) 496 (30) 1790 (88.3) 1387 (84.3)
Severe anaemia at baseline (Hb<7 g/dL) 288 (3.1) 9 (0.4) 14 (0.8) 4 (0.2) 175 (8.6) 86 (5.2)
History of fever last 24h 187 (2.2) 33 (2) 32 (2) 42 (3) 11 (1) 69 (7.5)
Fever (axillary temperature  37.5˚C) 97 (1) 16 (1) 34 (2) 5 (0.4) 6 (0.3) 36 (2.2)
Previous malaria episodes during current
pregnancy
292 (3.4) 85 (4) 3 (0.1) 22 (1.3) 0 (0) 182 (19.8)
Slept under a bednet the night before 3428 (40) 778 (38) 1824 (91) 119 (7) 1 (0.05) 706 (77)
Indoor residual spraying 2178 (29.4) 861 (42) 650 (32) 593 (36) 0 (0) 74 ‡ (4)
Antimalarials taken during pregnancy (as
treatment)
249 (2.9) 80 (4) 4 (0.4) 22 (1.3) 0 (0) 143 (16.7)
Taking malaria prophylaxis 45 (0.5) 11 (0.5) 1 (0.05) 2 (0.1) 0 (0) 31 (2)
n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) n/N (%)
Positive by microscopy P. vivax 73/9299 (0.8) 12/2025 (0.6) 2/2005 (0.1) 5/1584 (0.3) 25/2020 (1.2) 29/1665 (1.7)
P. falciparum 124/9305 (1.5) 12/2027 (0.6) 0/2005 (0) 0/1587 (0) 1/2021 (0.05) 111/1665 (6.7)
Positive for any
species
197/9326 (2.1) 24/2029 (1.2) 2/2005 (0.1) 5/1587 (0.3) 26/2021 (1.3) 140/1684 (8.3)
Positive by PCR P. vivax 124/1455 (8.5) 18/300 (6) 42/300 (14) 25/299 (8.4) 3/298 (1) 36/258 (13.9)
P. falciparum 80/1157 (6.9) 9/300 (3) 35/300 (11.6) 6/299 (2) NA (.) 30/258 (11.6)
Positive for any
species
182/1165 (15.6) 26/300 (8.7) 63/300 (21) 30/299 (10) NA (.) 63/266 (23.7)
* Arithmetic Mean (SD) [n].
† 1st trimester: 0–12 weeks, 2nd trimester: 13–24 weeks, 3rd trimester: 25–40 weeks.
‡ No indoor residual spraying (IRS) campaigns in the study area.
https://doi.org/10.1371/journal.pntd.0005606.t002
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Fig 2. Prevalence of P. vivax infection.
https://doi.org/10.1371/journal.pntd.0005606.g002
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Fig 3. Prevalence of P. falciparum infection. * Not available data. Technical problems in the performance
of the molecular analyses (PCR) for P. falciparum occurred at the reference laboratory in India. No biological
specimens remained available after that sufficient to repeat the analyses in an alternative laboratory.
https://doi.org/10.1371/journal.pntd.0005606.g003
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by PCR was 2.2% (26/1165), 0.3% (4/1191), 0.3% (1/379) at enrolment, delivery, and in cord
blood, respectively. No mixed infections were detected in the placental blood.
Data on malaria infection in the placenta are shown in Table 3. Data on congenital malaria
can be found in Table 4.
Table 3. Malaria infection in the placenta.
Overall Colombia Guatemala Brazil India Papua New
Guinea
Positive by microscopy
(impression smear)
n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) n/N (%)
P. vivax 13/3695 (0.3) 0/631 0 0/637 (0) 1/709 (0.14) 0/900 (0) 12/818 (1.5)
P. falciparum 32/3695 (0.8) 3/631 (0.5) 0/637 (0) 0/709 (0) 0/900 (0) 29/818 (3.5)
Positive for any species* 36/3702 (0.9) 3/635 (0.5) 0/637 (0) 1/709 (0.14) 0/903 (0) 32/818 (3.9)
Positive by PCR
P. vivax 19/503 (3.7) 2/100 (2) 14/102 (13.7) 0/95 (0) 0/100 (0) 3/106 (2.8)
P. falciparum 2/403 (0.5) 1/100 (1) 0/102 (0) 0/95 (0) − 1/101 (0.9)
Positive for any species * 21/403 (5.2) 3/100 (3) 14/102 (13.7) 0/95 (0) − 4/106 (3.7)
Classification of placental
infection by histology †
Active (acute + chronic) 49/1144 (4.3) 1/119 (0.8) 0/87 (0) 0/85 (0) 3/139 (2.2) 45/714 (6.3)
Past 92/1144 (8) 16/119 (13.4) 1/87 (1.1) 1/85 (1.2) 1/139 (0.7) 73/714 (10.2)
Not infected 1003/1144 (87.6) 102/119 (85.7) 86/87 (98.8) 84/85 (98.8) 135/139 (97.1) 596/714 (83.5)
Placental inflammation
Intervillous inflammation 158/1150 (13.7) 7/121 (5.7) 19/88 (21.6) 12/85 (14.1) 6/139 (4.3) 114/717 (15.9)
Infarcted areas 9/1150 (0.8) 7/121 (5.7) 1/88 (1.1) 0/85 (0) 1/139 (0.7) 0/717 (0)
* Whether P. vivax and/or P. falciparum. There were a total of 9 mixed infections (Pv+Pf) on the placental impression smear (by microscopy).
† Acute: parasites with no/mild pigment. Chronic: parasites + significant pigment deposition. Past: pigment with absence of parasites. Non-infected: no
evidence of parasites or pigment.
https://doi.org/10.1371/journal.pntd.0005606.t003
Table 4. Congenital malaria cases per country.
Overall Colombia Guatemala Brazil India Papua New
Guinea
Cord blood
Positive by microscopy n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) n/N (%)
P. vivax infection 2/4040 (0.05) 0/618 (0) 1/900 (0.1) 0/643 (0) 0/1183 (0) 1/696 (0.1)
P. falciparum infection 9/4040 (0.22) 1/618 (0.16) 0/900 (0) 0/643 (0) 0/1183 (0) 8/696 (1.15)
Any Plasmodium species 11/4061 (0.27) 1/636 (0.15) 1/900 (0.1) 0/643 (0) 0/1183 (0) 9/699 (1.3)
Positive by PCR
P. vivax infection 13/497 (2.6) 0/100 (0) 13/101 (12.8) 0/100 (0) 0/100 (0) 0/96 (0)
P. falciparum infection 7/385 (1.8) 3/100 (3) 2/101 (1.9) 1/100 (1) − 1/84 (1.2)
Any Plasmodium species 20/385 (5.2) 3/100 (3) 15/101 (14.8) 1/100 (1) − 1/96 (1.04)
Newborn blood
Positive by microscopy
P. vivax infection 1/4302 (0.02) 0/600 (0) 0/975 (0) 0/628 (0) 1/1174 (0.08) 0/925 (0)
P. falciparum infection 2/4303 (0.05) 0/600 (0) 0/975 (0) 0/629 (0) 0/1174 (0) 2/925 (0.2)
Any Plasmodium species 3/4309 (0.07) 0/600 (0) 0/975 (0) 0/629 (0) 1/1174 (0.08) 2/931 (0.2)
https://doi.org/10.1371/journal.pntd.0005606.t004
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Incidence of malaria
Data on incidence of malaria is shown in Table 5. The incidence rate of P. vivax infection
detected by microscopy was not associated with parity (Incidence Rate Ratio-IRR for multigra-
vidae-women with 4 or more pregnancies-, 1.14 [95% CI 0.70–1.87]; p = 0.619). For P. falcipa-
rum the IRR for multigravidae was 0.39, [95% CI 0.25–0.62]; p<0.001). A total of 898 passive
case detection visits (528 in PNG, 183 in CO, 75 in BR, 62 in GT and 50 in IN) were registered
among study women who reported symptoms or had signs suggestive of malaria infection. Of
those, 823 women had a blood smear collected, and in 141 (17%) of them malaria infection
was confirmed by microscopy; 68 cases were due to P. vivax, 72 cases were due to P. falcipa-
rum, and one case was due to P. malariae. In 85% (117/137) malaria episodes women were
found to be anemic (Hb<11g/dL) and 14% (19/137) severely anemic (Hb<7g/dL). Only 8
women with clinical malaria (2 with P. vivax and 6 with P. falciparum infection, and all from
CO) required hospital admission (data from admitted women in PNG not available). On aver-
age, 2% (86/4227) of study women reported at delivery a history of having had a malaria epi-
sode during the current pregnancy, and 2.3% (90/3830) having taken antimalarial drugs
during the same pregnancy. See S2 Table for incidence data disaggregated by PCD or ADI,
overall and by country.
Plasmodium parasite densities
Overall, parasite densities in pregnant women throughout the study were low in most cases.
The geometric mean density (GMD) for P. vivax infections on maternal peripheral blood at
any time during the study was 1275 parasites/μL (95% CI 906.5–1643.5); being 385 parasites/
μL (95% CI 226.9–543.1) and 2396 parasites/μL (95% CI 1579.5–3212.5) the GMDs for
P. vivax asymptomatic and symptomatic infections, respectively. The GMD for P. falciparum
infections on maternal peripheral blood was 1678 parasites/μL (95% CI 1268.6–2087.4); being
918 parasites/μL (95% CI 681.7–1154.3) and 4087 parasites/μL (95% CI 2362.1–5811.8) the
GMDs for P. falciparum asymptomatic and symptomatic infections, respectively.
Parasite densities on placental blood ranged for P. vivax from 0.6 parasites/μL in the posi-
tive case detected in Brazil to 25.5 parasites/μL arithmetic mean (SD 31.8) in PNG. For P. fal-
ciparum densities in the placenta ranged from 21.4 parasites/μL arithmetic mean (SD 25.5) in
CO up to 6255 parasites/μL arithmetic mean (SD 7845) in placentas from PNG.
Pregnancy outcomes
Overall, 10.2% (505/4943) of babies born to women enrolled in the study had LBW (range
2.8% in CO– 16.5% in PNG), and the prevalence of pre-term birth was 12.6% (455/3590)
across countries (Table 6). At delivery, on average 53.4% (2285/4278) of study women were
anemic (range 17.8% in BR– 88.3% in IN), and 4.5% of them (193/4278) were severely anemic.
Most of the documented deliveries (96%) took place at a health facility (hospital/health center)
attended by skilled staff. During the study follow up there were three maternal deaths and
their clinical diagnoses at the time of death were recorded; one in CO due to P. falciparum
malaria, one in PNG due to post-partum hemorrhage with no evidence of malaria at any time
during pregnancy, and one in IN associated with P. vivax malaria and anemia.
Impact of P. vivax and P. falciparum malaria on maternal and newborn
outcomes
At enrolment women with P. vivax or P. falciparum clinical malaria were more than 5-times
as likely to be anemic compared to non-infected women (adjusted OR, 5.48, [95% CI 1.82–
Plasmodium vivax infection in pregnancy
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16.41]; p = 0.009), and adjusted OR, 5.57, [95% CI 1.22–25.34]; p = 0.012, respectively)
(Table 7). In contrast, those women with clinical malaria at delivery, whether infected with
P. vivax (p = 0.754) or P. falciparum (p = 0.122), did not show an increased risk of anemia at
the same time point compared to non-infected or infected-asymptomatic women. No
Table 6. Pregnancy outcomes.
Overall Colombia Guatemala Brazil India Papua New
Guinea
Number of deliveries
registered (N)
4957 779 1025 860 1294 999
Gestational age (weeks) * 38.6 (3.0) [3590] 39.3 (2.3) [276] 39.5 (2.2) [948] 39.4 (1.5) [731] 38.5 (2.5) [576] 38.1 (4.3) [1059]
Birth weight * 3042 (507) [4943] 3235 (406) [776] 3127 (486) [992] 3249 (517) [869] 2812 (443) [1259] 2921 (511) [1047]
Haemoglobin mother (g/dL) * 10.4 (2.9) [4218] 10.8 (1.7) [669] 11.4 (1.6) [929] 12.0 (1.5) [696] 8.9 (1.6) [886] 9.6 (4.5) [1038]
n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) n/N (%)
Pre-term birth (<37 weeks) 455/3590 (12.6) 33/276 (12) 42/948 (4.4) 28/731 (3.8) 132/576 (23) 220/1059 (20.7)
Low birth weight (<2500g) 503/4901 (10.2) 22/776 (2.8) 68/992 (6.8) 64/836 (7.6) 176/1250 (14) 173/1047 (16.5)
Mother
Fever (axillary
temperature  37.5˚C)
142/4699 (3) 15/777 (1.9) 25/1025 (2.4) 11/719 (1.5) 41/1191 (3.4) 50/987 (5.06)
History of fever last 24h 38/4249 (0.9) 5/774 (0.6) 10/1024 (0.9) 2/726 (0.3) 0/1185 (0) 21/540 (3.9)
Overall anaemia at delivery
(Hb<11 g/dl)
2285/4278 (53.4) 345/669 (51.5) 337/1016 (33.1) 119/679 (17.8) 773/876 (88.3) 711/1038 (68.5)
Severe anaemia at delivery
(Hb<7 g/dL)
193/4278 (4.5) 7/669 (1.04) 7/1016 (0.7) 5/679 (0.72) 66/876 (7.5) 108/1038 (10.4)
Newborn
Prevalence of congenital
abnormalities
27/4890 (0.55) 8/737 (1.1) 6/1011 (0.6) 3/851 (0.3) 2/1181 (0.2) 9/1110 (0.1)
Fever (axillary
temperature  37.5˚C)
83/4644 (1.8) 2/735 (0.3) 7/979 (0.7) 0/707 (0) 64/1179 (5.4) 10/1044 (0.9)
* Arithmetic Mean (SD) [n]. Assessment of gestational age in GT, BR and PNG was done by Ballard method, an in Colombia and India by ultrasound.
https://doi.org/10.1371/journal.pntd.0005606.t006
Table 7. Impact of P. vivax and P. falciparum malaria on maternal anemia and low birth weight.
P. vivax P. falciparum
Maternal anaemia * Low birth weight Maternal anaemia Low birth weight
Adjusted
OR †
(95% CI) p-value Adjusted OR (95% CI) p-value Adjusted OR (95% CI) p-value Adjusted OR (95% CI) p-value
At enrolment
Non-infected 1 0.009 1 0.350 1 0.001 1 0.092
Asymptomatic
malaria infection
0.96 (0.37–2.44) 0.92 (0.21–4.14) 4.01 (1.59–10.11) 2.03 (1.07–3.85)
Clinical malaria 5.48 (1.83–16.41) 2.29 (0.74–7.04) 5.57 (1.22–25.34) 1.39 (0.16–12.03)
At delivery
Non-infected 1 0.754 1 0.298 1 0.122 1 0.004
Asymptomatic
malaria infection
0.66 (0.22–1.96) 1.01 (0.22–4.63) 8.19 (1.08–62.38) 4.52 (1.63–12.49)
Clinical malaria 1.05 (0.07–15.58) 9.39 (0.56–158.25) 1.29 (0.23–7.18) 4.29 (0.70-26-24)
Non-infected 1 0.384 1 0.895 1 <0.001 1 0.001
Microscopic
infection
0.62 (0.22–1.81) 0.90 (0.20–4.10) 4.07 (1.93–8.58) 4.28 (1.75–10.44)
Non-infected 1 0.717 1 0.110 1 0.402 1 0.359
Sub-microscopic
infection ‡
1.16 (0.52–2.59) 0.52 (0.23–1.16) 2.93 (0.24–36.23.16) 1.97 (0.46–8.46)
* Arithmetic Mean (SD) [n]. Assessment of gestational age in GT, BR and PNG was done by Ballard method, an in Colombia and India by ultrasound.
https://doi.org/10.1371/journal.pntd.0005606.t007
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association was found between P. vivax or P. falciparum clinical malaria at enrolment
(p = 0.100, and p = 0.760, respectively) or at delivery (p = 0.120, and p = 0.060, respectively)
and an increased risk of LBW.
Women with P. vivax malaria at delivery detected by microscopy did not have an increased
risk of anemia (adjusted OR, 0.62, [95% CI 0.22–1.81]; p = 0.384) or LBW (adjusted OR, 0.90,
[95% CI 0.20–4.10]; p = 0.895), compared to uninfected women. However, those women with
P. falciparum malaria showed an increased risk for both anemia (adjusted OR, 4.07, [95% CI
1.93–8.58]; p = 0.0002) and LBW (adjusted OR, 4.28, [95% CI 1.75–10.44]; p = 0.0014). In the
nested case-control sub-analysis, women with P. vivax submicroscopic infection at delivery
did not show an increased risk of moderate-severe anemia (adjusted OR, 1.16, [95% CI 0.52–
2.59]; p = 0.717) or LBW (adjusted OR, 0.52, [95% CI 0.23–1.16]; p = 0.110) compared to unin-
fected women (negative by microscopy and by PCR). Likewise, P. falciparum submicroscopic
infections at delivery were not associated with moderate-severe anemia (adjusted OR, 2.93,
[95% CI 0.24–36.23]; p = 0.402) or LBW (adjusted OR, 1.97, [95% CI 0.46–8.46]; p = 0.359).
Malaria infection in the placenta (whether detected by impression smear or PCR) was not
associated with an increased risk of LBW (adjusted OR, 0.67, [95% CI 0.07–6.18]; p = 0.725 for
P. vivax, and adjusted OR, 8.61, [95% CI 0.79–94.09]; p = 0.077, for P. falciparum) or anemia
(adjusted OR, 2.04, [95% CI 0.70–5.92]; p = 0.189 for P. vivax, and adjusted OR, 0.77, [95% CI
0.16–3.67]; p = 0.746, for P. falciparum). In contrast, a statistically significant association was
found for placental infections detected by histology with LBW (adjusted OR, 2.36, [95% CI
1.48–3.76]; p =<0.001) and anemia (adjusted OR, 1.66, [95% CI 1.09–2.51]; p = 0.017). Histol-
ogy did not allow distinguishing between species, but of the infected placentas according to
histology a higher proportion were positive for P. falciparum (11.4%) compared to P. vivax
(4.8%) by impression smear or PCR.
Discussion
This is, to our knowledge, the first multicenter prospective observational study on the burden
of P. vivax in pregnant women from different malaria endemic areas. Overall, the proportion
of pregnant women attending the ANC who were infected with vivax malaria detected by
microscopy was low across the different endemic settings included in the study. However,
P. vivax infection in pregnancy was associated with negative consequences for maternal health
in those that were symptomatic, which may have a negative impact also for the health of the
neonate. Importantly, most of the P. vivax infections in pregnancy were undetected with
microscopy, the routinely used screening method across study sites.
The majority of the information on P. vivax in pregnancy comes from studies carried out in
Asia. [19] There is much less information from Latin America, where P. vivax is responsible
for 65 to 100% of malaria cases;[26] a community-based study conducted in the Brazilian
Amazon in 2002 showed that 1.9% of the pregnant women were infected with P. vivax,[27]
and a study from Colombia conducted between 2005 and 2011 reported that 11.6% of preg-
nant women were infected at delivery with P. vivax. [28] However, in the current study, the
frequency of P. vivax infection detected by microscopy was below 2% in all countries and at all
time points. Recent efforts in the deployment of malaria preventive measures, as it was the
case of Guatemala in this study, together with the introduction of new more effective antima-
larial drugs for case management, may have played a role in the decrease in the prevalence of
infections observed in this study below microcopy-detection levels, but still allowing a consid-
erable proportion of the population harboring sub-microscopic parasitemia levels.
Mixed infections were rare, except in PNG, which is different from the situation in Africa
where most non-falciparum infections in pregnancy are mixed infections. [29] Histology was
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the method showing the highest sensitivity for detection of malaria infection in the placenta
compared to microscopy and PCR, and the presence of malaria pigment more frequent than
of parasites in the infected placentas.
In most study countries, optical microscopy is used for case detection of malaria infection,
[26] and for routine screening of malaria at ANC visits (where the latter is recommended).
However, the fact that PCR methods detected significantly more infections than microscopy
suggest that many infections were undetected and that microscopy is not a sensitive method
for routine screening of malaria, particularly in P. vivax endemic areas due to the generally low
parasite densities. [30]
The available data on the impact of P. vivax in pregnancy are scarce, and they have rarely
been analysed disaggregated from the effects of P. falciparum infection. Thus, understanding
the main effects of P vivax monoinfection in pregnancy was a main objective of this study. It
was observed that during pregnancy pregnant women with clinical P. vivax monoinfection
had a 5-fold higher risk of having anemia (Hb<11g/dL) compared to non-infected women. In
malaria endemic areas, there is evidence on the impact of maternal anemia on maternal mor-
tality and morbidity,[31] as well as on neonatal and infant health and survival. [6, 8] In con-
trast, asymptomatic P. vivax infection was not associated with an increased risk of maternal
anemia of any degree. The evidence from this study also indicated that it is rare for P. vivax,
and for P. falciparum to establish an infection in the newborn.
The two maternal deaths reported in Colombia and India were associated with P. falcipa-
rum and P. vivax infections, respectively, underpinning that malaria in pregnancy can be a
contributor to maternal mortality in these low transmission settings. These results claim the
maternal and neonatal health programs in P. vivax endemic areas to recognize that vivax
malaria is associated with negative consequences for the health of pregnant women and conse-
quently for that of the neonate. Clinical and epidemiologic surveillance systems need to be
integrated into maternal and reproductive health programs to detect malaria cases in pregnant
women for prompt and effective case management.
The results of this study can also contribute to evaluate whether current strategies for
malaria control during pregnancy adopted in areas where P. vivax is predominant are ade-
quate, and if they are aligned with most recent evidence. In this study, performance of passive
surveillance was better in detecting Plasmodium infections (17% positivity by blood smear
among women with malaria symptoms) compared to active detection at routine visits (2.1%
and 0.94% of women infected at enrolment and at delivery visits, respectively). As malaria
transmission diminishes, the approach to the detection of infected pregnant women may
change from active detection at each ANC visit to passive detection to capture the infections
(febrile, symptomatic cases) that are mostly associated with poor pregnancy outcomes. As
malaria burden decreases the sustainability of an active approach might be questionable, as
shown in some countries in the Americas, nor cost-effective. Surveillance is of particular rele-
vance for those countries that are in the pathway towards malaria elimination and will need to
shift from measuring reductions in morbidity and mortality, to detecting infections and mea-
suring transmission.
P. vivax is becoming the dominant species in low transmission areas. [26] Accurate data on
P. vivax burden depending on the level of malaria endemicity is crucial to designing effective
malaria control and elimination policies. However, P. vivax poses unique epidemiological
challenges. In contrast to P. falciparum, P. vivax can arise from dormant hypnozoites leading
to relapses weeks or months after, that can be indistinguishable from a primary infection. [32]
The prevention of these relapses is considered to be the most important strategy for interrupt-
ing P. vivax transmission. [33] In pregnant women the use of primaquine, a member of the
8-aminoquinoline family and the only drug currently licensed for radical cure of P. vivax
Plasmodium vivax infection in pregnancy
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005606 June 12, 2017 17 / 22
malaria, is contraindicated for safety reasons, putting them at a higher risk of clinical relapses.
The role that pregnant women may play as asymptomatic parasite reservoirs needs to be
further investigated, as this might represent a limitation for effective malaria control and
elimination.
There are limitations to this study. The study was able to capture data and collect samples
from pregnant women at the time of delivery for more than half of study women, but this still
represented a low follow-up rate. This limitation is not uncommon in health facility based
studies from settings where most women deliver at home,[34] as it was the case for most of
study sites. Comparison of baseline characteristics between complete and lost to follow-up
women showed that differences were related primarily to characteristics of the site or site-
related, Although statistical analyses were adjusted by site, these dissimilarities need to be care-
fully considered as this may imply that the findings might not be generalized to the women
who do not deliver at the health facility.
The evaluation of gestational age ultrasound assessment was not available at those facilities,
and the Ballard0s method was used in some of the study countries. This might represent a limi-
tation, as the latter is not as reliable method as ultrasound is. PCR assays for detection of
malaria infection were performed at a different laboratory in India due to regulatory issues
that did not allow analyzing samples at the study central laboratory at the ISS in Rome.
Although the same standardized protocols were used in both laboratories, and that internal
and external validations were performed in a subset of samples, this might have introduced
some potential bias by pooling of data obtained from different laboratories. In addition, much
of the data shown in this study is reported as aggregate to provide an estimate of the wider geo-
graphic situation. However, the interpretation of these data has to take into consideration the
differences in some of the estimates across sites. Also, some women (2.4%) reported having
received antimalarial treatment during pregnancy. Though analyses of the impact of micro-
scopic and sub-microscopic infection were adjusted by previous malaria episodes and study
site, it needs to be taken into consideration as this may have impacted the results. Lastly, the
low proportion of microscopically detected infections and that PCR determination of malaria
infection could not be performed in all samples did represent a limitation for the pooled analy-
sis on the impact of microscopic and submicroscopic infections. The lack of association of sub-
microscopic and placental infections (except those detected by histology) with anemia and
LBW needs to be viewed with caution as it could be related to a sample size issue, and thus not
being enough placental infections to detect a clinically important difference.
Conclusions
This multicenter study in representative areas endemic for vivax malaria shows that the preva-
lence of P. vivax malaria was overall low across study sites. However, the prevalence of submi-
croscopic infections was significant in some areas, which may have implications for detection
of malaria infections with the currently used diagnostic tools. Clinical episodes due to P. vivax
infection were associated with maternal anemia, which may be also detrimental for infant’s
health. These findings can be relevant for guiding maternal health programs in settings where
vivax malaria is endemic, as well as for monitoring, evaluation and surveillance activities in
countries that are in the pathway towards malaria elimination.
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